HIV Prevention Clinical Trial
Official title:
The PrEPARE Project: Prevention, Empowering, and Protecting Young Women in South Africa
NCT number | NCT04048551 |
Other study ID # | R01HD094629 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 4, 2019 |
Est. completion date | June 23, 2022 |
Verified date | September 2022 |
Source | RTI International |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The project seeks to determine whether implementing a multilevel, woman-focused intervention, the Young Women's Health CoOp (YWHC), for pre-exposure prophylaxis (PrEP) readiness, uptake, and adherence is a viable complement to the HIV prevention plan for the Government of South Africa. Specifically, this project aims to: increase uptake, of sexual and reproductive health (SRH) services and readiness and uptake of PrEP among adolescent girls and young women (AGYW) aged 16 to 24 who engage in high-risk sexual behaviors; and reduce their barriers to accessing SRH services by addressing and reducing stigma and discrimination (S&D) in clinics.
Status | Completed |
Enrollment | 802 |
Est. completion date | June 23, 2022 |
Est. primary completion date | June 23, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 16 Years to 24 Years |
Eligibility | Inclusion Criteria: - HIV negative - identify as female; - aged 16-24; - have had condomless sex in the past 3 months with a male partner; - not be currently pregnant and not want to get pregnant for the next year; - interested in taking PrEP; - not having previously participated in the formative phase of the study; - have not previously and not currently participating in any other PrEP-related demonstration project or research study; - not previously or not currently participating in any other HIV study in Tshwane; - lives in one of the target communities; - not on multidrug-resistant tuberculosis (MDR-TB) treatment; - intends to stay in the Tshwane district for the next 12 months; - agrees to provide contact information; - be willing to undergo rapid HIV testing; - be willing to undergo pregnancy testing. Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
South Africa | Setshaba Research Centre | Soshanguve |
Lead Sponsor | Collaborator |
---|---|
RTI International | Setshaba Research Centre |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Health Clinic-Level Outcome: Level of Health Clinic Stigma and Discrimination | Staff surveys that are modified from the Health Policy Project survey will be used to measure healthcare staffs' attitudes toward sexually active AGYW; the overall clinic environment; observed discrimination and stigmatizing behaviors toward AGYW. Greater values indicate higher levels of health clinic stigma and discrimination. | Baseline | |
Primary | Health Clinic-Level Outcome: Level of Health Clinic Stigma and Discrimination | Staff surveys that are modified from the Health Policy Project survey will be used to measure healthcare staffs' attitudes toward sexually active AGYW; the overall clinic environment; observed discrimination and stigmatizing behaviors toward AGYW. Greater values indicate higher levels of health clinic stigma and discrimination. | 4 months | |
Primary | Health Clinic-Level Outcome: Level of Health Clinic Stigma and Discrimination | Staff surveys that are modified from the Health Policy Project survey will be used to measure healthcare staffs' attitudes toward sexually active AGYW; the overall clinic environment; observed discrimination and stigmatizing behaviors toward AGYW. Greater values indicate higher levels of health clinic stigma and discrimination. | 8 months | |
Primary | Health Clinic-Level Outcome: The Number of AGYW who Uptake HIV and SRH services, including PrEP | A clinic audit, including a review of administrative data, will be conducted to assess the number of AGYW who uptake HIV and sexual and reproductive health services, including PrEP in each clinic. | Baseline | |
Primary | Health Clinic-Level Outcome: The Number of AGYW who Uptake HIV and SRH services, including PrEP | A clinic audit, including a review of administrative data, will be conducted to assess the number of AGYW who uptake HIV and sexual and reproductive health services, including PrEP in each clinic. | 4 months | |
Primary | Health Clinic-Level Outcome: The Number of AGYW who Uptake HIV and SRH services, including PrEP | A clinic audit, including a review of administrative data, will be conducted to assess the number of AGYW who uptake HIV and sexual and reproductive health services, including PrEP in each clinic. | 8 months | |
Primary | AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW | Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures developed for this study and from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. | Baseline | |
Primary | AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW | Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. | 3 months | |
Primary | AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW | Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. | 6 months | |
Primary | AGYW Participant Self-Report: The Level of PrEP Readiness among AGYW | Self-report responses to a modified scale from the HIV Prevention Trials Network (HPTN) 082 trial and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess the extent to which AGYW are ready to initiate PrEP. Greater values indicate higher levels of PrEP readiness. | 9 months | |
Primary | AGYW Participant Self-Report: PrEP Uptake and Adherence among AGYW | Self-report responses to a modified scale from Microbicide Trials Network Studies (MTN) and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated PrEP. Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess PrEP adherence, including past 30-day use, and patterns of use, persistence and discontinuation. | 3 months | |
Primary | AGYW Participant Self-Report: PrEP Uptake and Adherence among AGYW | Self-report responses to a modified scale from Microbicide Trials Network Studies (MTN) and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated PrEP. Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess PrEP adherence, including past 30-day use, and patterns of use, persistence and discontinuation. | 6 months | |
Primary | AGYW Participant Self-Report: PrEP Uptake and Adherence among AGYW | Self-report responses to a modified scale from Microbicide Trials Network Studies (MTN) and single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated PrEP. Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess PrEP adherence, including past 30-day use, and patterns of use, persistence and discontinuation. | 9 months | |
Primary | AGYW Biological Outcome: Adherence to PrEP | Dried blood spot samples will be used to measure the amount of drug (Tenofovir-diphosphate) concentration in AGYW's blood to assess PrEP adherence. | 3 months | |
Primary | AGYW Biological Outcome: Adherence to PrEP | Dried blood spot samples will be used to measure the amount of drug (Tenofovir-diphosphate) concentration in AGYW's blood to assess PrEP adherence. | 6 months | |
Primary | AGYW Biological Outcome: Adherence to PrEP | Dried blood spot samples will be used to measure the amount of drug (Tenofovir-diphosphate) concentration in AGYW's blood to assess PrEP adherence. | 9 months | |
Primary | AGYW Participant Self-Report: Sexual and Reproductive Health Uptake among AGYW | Self-report responses on the single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated SRH services. | 3 months | |
Primary | AGYW Participant Self-Report: Sexual and Reproductive Health Uptake among AGYW | Self-report responses on the single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated SRH services. | 6 months | |
Primary | AGYW Participant Self-Report: Sexual and Reproductive Health Uptake among AGYW | Self-report responses on the single item measures from the adapted Risk Behavior Assessment (RBA) questionnaires will be used to assess if AGYW initiated SRH services. | 9 months | |
Secondary | AGYW Participant Self-Report: Frequency of Drug Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting. | Baseline | |
Secondary | AGYW Participant Self-Report: Frequency of Drug Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting. | 3 months | |
Secondary | AGYW Participant Self-Report: Frequency of Drug Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting.. | 6 months | |
Secondary | AGYW Participant Self-Report: Frequency of Drug Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of drug (e.g, methamphetamine) use and injecting. | 9 months | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption. | Baseline | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption | 3 months | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption | 6 months | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of days of alcohol consumption and the number of days of problematic (4+) alcohol consumption. | 9 months | |
Secondary | AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. | baseline | |
Secondary | AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. | 3 months | |
Secondary | AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. | 6 Months | |
Secondary | AGYW Participant Self-Report: Frequency of Combining Drugs and Alcohol Use | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of combining drugs with alcohol. | 9 months | |
Secondary | AGYW Participant Self-Report: Frequency of Condom Use | Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. | Baseline | |
Secondary | AGYW Participant Self-Report: Frequency of Condom Use | Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. | 3 months | |
Secondary | AGYW Participant Self-Report: Frequency of Condom Use | Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. | 6 months | |
Secondary | AGYW Participant Self-Report: Frequency of Condom Use | Self-report responses on single-item questions will be used to assess condom use. Condom use will be calculated as a count and percentage (based on the total number of acts and the numbers of acts with a condom). Lower percentage values indicate less frequent condom use. For the count variable, greater values indicate more acts of sex without a condom. | 9 months | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex | Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. | Baseline | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex | Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. | 3 months | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex | Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. | 6 months | |
Secondary | AGYW Participant Self-Report: Frequency of Alcohol and Other Drug Use Prior to or During Sex | Self-report responses on single-item questions from the Pretoria Risk Behavior Assessment will be used to assess engagement in alcohol and other drug use prior to or during sex. | 9 months | |
Secondary | AGYW Participant Self-Report: Number of Other Sex Partners | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. | Baseline | |
Secondary | AGYW Participant Self-Report: Number of Other Sex Partners | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. | 3 months | |
Secondary | AGYW Participant Self-Report: Number of Other Sex Partners | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. | 6 months | |
Secondary | AGYW Participant Self-Report: Number of Other Sex Partners | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the number of other sex partners among AGYW. | 9 months | |
Secondary | AGYW Participant Self-Report: Engagement in Sex Trading | Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. | Baseline | |
Secondary | AGYW Participant Self-Report: Engagement in Sex Trading | Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. | 3 months | |
Secondary | AGYW Participant Self-Report: Engagement in Sex Trading | Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. | 6 months | |
Secondary | AGYW Participant Self-Report: Engagement in Sex Trading | Self-report responses on single-item measures modified from the Pretoria Risk Behavior Assessment (PRBA) will be used to assess whether participants engaged in trading sex for money or other things. | 9 months | |
Secondary | AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. | Baseline | |
Secondary | AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. | 3 months | |
Secondary | AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. | 6months | |
Secondary | AGYW Participant Self- Report: Engagement with multiple sex partners (= 2 partners) | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess engagement with more than one sex partner in the past 3 months. | 9 months | |
Secondary | AGYW Participant Self-Report: Use of Contraception | Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. | Baseline | |
Secondary | AGYW Participant Self-Report: Use of Contraception | Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. | 3 months | |
Secondary | AGYW Participant Self-Report: Use of Contraception | Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. | 6 months | |
Secondary | AGYW Participant Self-Report: Use of Contraception | Self-report responses on single-item measures will be used to assess use of contraception and types of contraception among AGYW. | 9 months | |
Secondary | Medical Record: Use of Contraception | Clinical medical record will be used to assess contraception and contraception type among AGYW. | Through study completion, an average of nine months | |
Secondary | AGYW Participant Self-Report: Level of Perception of HIV Risk | Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. | Baseline | |
Secondary | AGYW Participant Self-Report: Level of Perception of HIV Risk | Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. | 3 months | |
Secondary | AGYW Participant Self-Report: Level of Perception of HIV Risk | Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. | 6 months | |
Secondary | AGYW Participant Self- Report; Level of Perception of HIV Risk | Self-report responses on single-item questions will be used to assess the extent to which AGYW perceive themselves as at risk for HIV infection. Higher levels indicate greater perceived HIV risk. | 9 months | |
Secondary | AGYW Participant Self-Report: The Frequency of Experienced Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW.
. |
Baseline | |
Secondary | AGYW Participant Self-Report: The Frequency of Experienced Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW.
. |
3 months | |
Secondary | AGYW Participant Self-Report: The Frequency of Experienced Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW. | 6 months | |
Secondary | AGYW Participant Self-Report: The Frequency of Experienced Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to assess the frequency of experiencing stigma or discrimination from clinic staff or community members among AGYW. | 9 months | |
Secondary | AGYW Participant Self-Report: The Level of Anticipated Stigma | Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma. | Baseline | |
Secondary | AGYW Participant Self-Report: The Level of Anticipated Stigma | Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma. | 3 months | |
Secondary | AGYW Participant Self-Report: The Level of Anticipated Stigma | Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma. | 6 months | |
Secondary | AGYW Participant Self-Report: The Level of Anticipated Stigma | Self-report responses on single-item questions and multiple-item scales developed from the formative research study activities will be used to assess the extent to which AGYW anticipate stigma or discrimination from clinic staff or community members. Higher values indicate greater levels of anticipated stigma.
. |
9 months | |
Secondary | AGYW Participant Self-Report: The Frequency of Observed Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. | Baseline | |
Secondary | AGYW Participant Self-Report: The Frequency of Observed Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. | 3 months | |
Secondary | AGYW Participant Self-Report: The Frequency of Observed Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. | 6 months | |
Secondary | AGYW Participant Self-Report: The Frequency of Observed Stigma | Self-report responses on the AGYW questionnaire adapted from previous research will be used to the assess the frequency that AGYW have witnessed stigma or discrimination from clinic staff or community members toward sexually active AGYW. | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
Active, not recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
Completed |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
Completed |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |